Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2011

View Archived Issues

Selective SYK inhibitors P505-15 and P459-72 show anticancer potential

Anti-HIV-1 activity of aciclovir and potentiation by ribavirin

Tekmira Pharma begins phase I trial of TKM-080301 in solid tumors

New antagonists of melanin-concentrating hormone MCH1 receptor claimed

Apricus Biosciences grants Bracco rights to market Vitaros in Italy

New CGRP receptor antagonists identified by Boehringer Ingelheim

Phase II trial evaluates CK-2017357 in generalized myasthenia gravis

New antagonists of voltage-gated potassium channels claimed by Xention

FDA approves generic version of Doryx

Vascular Biogenics begins phase II trials of VB-111 in glioblastoma and thyroid cancer

Novartis researchers claim novel PI3K and mTOR inhibitors

BioCryst Pharma begins phase IIb trial of BCX-4208 as add-on therapy for gout

Advanced Cell Technology enters stock purchase agreement with Socius

BioSante raises funds for phase III LibiGel program

Phase II data presented on AIC-246 for human cytomegalovirus infection

Cumberland Pharma voluntarily recalls six lots of Acetadote in U.S.

IMMU-114 shows potential for treating GVHD

Lundbeck completes two phase III trials of nalmefene for alcohol dependence

McKesson acquires US Oncology

BL-5010 is efficacious in nonsurgical removal of skin lesions in phase I/II trial

Proteome Sciences and Janssen Pharmaceutica enter into collaboration

MK-2461 is active in model of multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...